Anti-Inflammatory Activities of a Chinese Herbal Formula IBS-20 (IBS/IBD Support) In Vitro and In Vivo

Yang Zh, Grinchuk V, Ip SP, et al. Evidence-Based Complementary and Alternative Medicine. Volume 2012 (2012). doi:10.1155/2012/491496

Irritable bowel syndrome (IBS) is a functional bowel disorder with an incompletely understood aetiology. There is currently no cure for IBS, and no existing medication induces symptom relief in all patients. IBS-20 is a 20-herb Chinese medicinal formula that has shown beneficial effects in patients with IBS; however, the underlying mechanisms have been largely unknown.

This study demonstrated that IBS-20 potently inhibited LPS- or IFNγ-stimulated expression of pro-inflammatory cytokines, as well as the classically activated macrophage marker nitric oxide synthase 2. Similarly, IBS-20 or the component herb Coptis chinensis decreased LPS-stimulated pro-inflammatory cytokine secretion from JAWS II dendritic cells. IBS-20 or its component herbs also blocked or attenuated the IFNγ-induced drop in transepithelial electrical resistance — an index of permeability — in fully differentiated Caco-2 monolayers.

Finally, in TNBS-treated mice, a model of colonic inflammation, oral administration of IBS-20 significantly suppressed the up-regulation of key inflammatory cytokines, including IFNγ and IL-12p40, in the inflamed colon. These findings indicate that the anti-inflammatory activities of IBS-20 may contribute to its beneficial effects in patients with IBS, providing a potential mechanism of action for the formula.

Control of intestinal permeability is critical for host defence, as enhanced permeability facilitates passage of large numbers of intraluminal bacteria, antigens, and other pathogen-derived molecules across the mucosal barrier, triggering immune activation (Turner, 2009). Evidence suggests that IBS patients exhibit increased mucosal permeability in the small intestine or colon irrespective of IBS subtype, often correlating with disease severity. Changes in mucosal barrier function and the resulting immune activation are also involved in triggering visceral hypersensitivity in IBS (Piche et al., 2009). This study showed that IBS-20 and its component herbs are able to preserve normal mucosal barrier function, providing another plausible mechanism for its beneficial effects.

One key upstream driver of pro-inflammatory cytokines in gut inflammation is the NLRP3 inflammasome — a multiprotein complex central to the innate immune system. NLRP3 detects cellular damage or microbial invasion, activating caspase-1, which then processes and releases IL-1β and IL-18. While this mechanism is vital for host defence, excessive or chronic activation of NLRP3 has been implicated in several inflammatory diseases, including IBS and IBD. The ability of IBS-20 to suppress key cytokines downstream of NLRP3 suggests it may indirectly modulate inflammasome-driven inflammation, adding another dimension to its anti-inflammatory profile.

Moreover, IBS-20 is capable of suppressing the up-regulation of inflammatory cytokines in the inflamed colon in vivo. However, in TNBS-treated mice, IBS-20 did not significantly improve clinical symptoms or histological abnormalities of the colon. This could be due to factors such as the inability to inhibit TNBS-induced epithelial barrier breakdown or block IL-1β production — a major cytokine implicated in TNBS-induced colonic inflammation.

Collectively, these results demonstrate that IBS-20 possesses strong anti-inflammatory properties. The herbal extracts inhibit pro-inflammatory cytokine production from immune cells, protect epithelial barrier integrity, and may modulate inflammasome-related pathways. Given the similarities and clinical overlaps between IBS and other gut inflammatory diseases (Bercik et al., 2005), IBS-20 may also be a potential therapeutic agent for other Th1-dominant gut pathologies such as inflammatory bowel disease.

Stress, the HPA Axis, and IBS Pathophysiology

There is an absolute relationship between IBS and stress, rooted in the way the body responds to internal or external changes. This “stress response,” also known as the fight-or-flight reaction, evolved to maximise survival during life-threatening situations. It involves complex interactions between the nervous and endocrine systems, leading to changes in blood pressure, heart rate, muscle tension, immune activity, and bowel function. These changes in gastrointestinal motility and sensitivity directly link stress responses to IBS symptomatology.

The Brain–Gut Connection

When a stressor is perceived, brain regions such as the sensory cortex, thalamus, and brainstem initiate responses via two major pathways:

1. Hypothalamic–Pituitary–Adrenal (HPA) Axis – culminating in cortisol release, which influences immune activity, metabolism, and gut physiology.
2. Autonomic Nervous System (ANS) – triggering release of adrenaline and noradrenaline, affecting cardiovascular, muscular, and gastrointestinal systems.

Both pathways communicate bidirectionally with the enteric nervous system, which governs gut function. This brain–gut crosstalk helps explain how psychological stress can exacerbate intestinal permeability, inflammation, and visceral hypersensitivity — processes already implicated in IBS pathogenesis.

Inflammatory Pathways in the Stress Response

The stress response not only alters motility but also impacts mucosal immunity. For example, corticotropin-releasing factor (CRF) receptors in the gut influence epithelial barrier integrity, secretion patterns, and pain signalling. Chronic activation of the HPA axis can perpetuate low-grade inflammation through sustained cytokine production, potentially amplifying NLRP3 inflammasome activity. This mechanistic overlap suggests that interventions which modulate both stress physiology and inflammatory pathways — such as IBS-20 — may offer broader therapeutic benefit.

Clinical Relevance

While anxiety and stress do not directly cause IBS, they can heighten symptom severity and frequency by increasing gut sensitivity and promoting immune activation. Strategies to address both inflammation (e.g., via botanical interventions) and stress (e.g., relaxation techniques, lifestyle modifications) may therefore be the most effective approach for long-term management.

References

1. Yang Zh, Grinchuk V, Ip SP, et al. Anti-inflammatory activities of a Chinese herbal formula IBS-20 (IBS/IBD Support) in vitro and in vivo. Evid Based Complement Alternat Med. 2012;2012:491496. doi:10.1155/2012/491496.
2. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9(11):799–809. doi:10.1038/nri2653.
3. Piche T, Barbara G, Aubert P, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut. 2009;58(2):196–201. doi:10.1136/gut.2007.140806.
4. Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am. 2005;34(2):235–245. doi:10.1016/j.gtc.2005.02.004.
5. Fioramonti J, Gebhart GF. In vivo and transgenic animal models used to study visceral hypersensitivity. Neurogastroenterol Motil. 2007;19(1):20–28. doi:10.1111/j.1365-2982.2006.00873.x.
6. Hughes PA, Brierley SM, Martin CM, et al. Post-inflammatory colonic afferent sensitisation: different subtypes, different pathways and different time courses. Gut. 2009;58(10):1333–1341. doi:10.1136/gut.2008.162503.
7. Wirtz S, Neurath MF. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev. 2007;59(11):1073–1083. doi:10.1016/j.addr.2007.07.003.
8. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain. 2009;146(1-2):41–46. doi:10.1016/j.pain.2009.06.017.
9. Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20(13):3328. doi:10.3390/ijms20133328.
10. Zhen Y, Zhang H. NLRP3 inflammasome and inflammatory bowel disease. Front Immunol. 2019;10:276. doi:10.3389/fimmu.2019.00276.
11. Chassaing B, Aitken JD, Malleshappa M, Vijay-Kumar M. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol. 2014;104:15.25.1–15.25.14. doi:10.1002/0471142735.im1525s104.